Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine

Depression Clinical Trial

— (IRLGREY-B)  

Official title:

Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02263248
• Other study ID #: 035/2014
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: December 2014
• Est. completion date: May 1, 2018

Study information

• Verified date: July 2018
• Source: Centre for Addiction and Mental Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patient with difficult to treat depression . This research study is testing whether combining two medications will be effective in treating depression when initial treatment with just one antidepressant does not relieve the depressive symptoms ; this is what is called " difficult to treat depression " or " treatment resistant depression ". The two medication the investigators are using are " an anti-depressant medication called venlafaxine XR ( the generic form of Effexor ) and buprenorphine . Buprenorphine is a medication that is FDA approved for the treatment of opioid dependence. The investigators are testing whether adding buprenorphine to venlafaxine enhances treatment response.

Description:

The aim of this study is to examine the feasibility, safety, and tolerability of buprenorphine (BPN) as a novel treatment for late-life treatment resistant depression (LL-TRD). The investigators aim to use a clinical trial methodology common to all three sites, and to examine the mechanism of action (MOA) of BPN using translational neuroscience methods. Over ½ of seniors with depression fail to respond to traditional antidepressants.19,20 Modulation of the opiate system with BPN offers a novel mechanistic approach to improve the lives of patients with LL-TRD, with a safety profile potentially superior to current augmentation strategies such as antipsychotics, lithium, ECT, and surgical interventions (e.g., deep brain or vagal nerve stimulation).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: May 1, 2018
• Est. primary completion date: January 19, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

1. Age > 50 years

2. Major depressive disorder (MDD), single or recurrent, as diagnosed by the SCID-IV (or SCID-5 if available)

3. MADRS > 15

4. Has or agrees to establish a clinical relationship with primary care physician (PCP).

5. Availability of an informant (e.g., emergency contact) is encouraged but not required for study participation

Exclusion Criteria:

1. Inability to provide informed consent

2. Depressive symptoms not severe enough (i.e., MADRS < 15) at the baseline assessments

3. Dementia, as defined by 3MS < 80 and clinical evidence of dementia

4. Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms, as diagnosed by the SCID

5. Abuse of or dependence on alcohol or other substances within the past 3 months as determined by SCID, and score of > 8 on AUDIT-C and confirmed by study physician interview

6. High risk for suicide (e.g., active SI and/or current/recent intent or plan) AND unable to be managed safely in the clinical trial (e.g., unwilling to be hospitalized). Urgent psychiatric referral will be made in these cases

7. Contraindication to venlafaxine or buprenorphine as determined by PCP and study physician including history of intolerance of either venlafaxine or buprenorphine in the study target dosage range (venlafaxine at up to 300 mg/day; buprenorphine at up to 1.2 mg/day)

8. Inability to communicate in English (i.e., interview cannot be conducted without an interpreter; subject largely unable to understand questions and cannot respond in English)

9. Non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview)

10. Unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management. This will be determined based on information from the patient's personal physician and study physician's clinical judgment. Referral to the patient's personal physician or to a general practitioner will be made in these cases

11. Subjects taking psychotropic medications that cannot be safely tapered and discontinued prior to study initiation. The following exceptions are allowed if they have been taken at a stable dose for at least 4 weeks prior to study entry and there is not a plan to change the dose during the next 32 -36 weeks: benzodiazepines up to 2 mg/d lorazepam equivalent; other sedative-hypnotics (e.g., zolpidem, zaleplon, eszopiclone); gabapentin if prescribed for non-psychiatric indication (e.g., neuropathy)

12. History of opiate abuse or dependence

13. Severe pain, defined as > 7 on 0-10 numeric rating scale for pain

14. Concomitant use of strong or moderate CYP3A4 inhibitor (indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketonazole, nefazodone, saquinovir, telithromycin, aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil, diltiazem)

15. Refusal to stop all opioids (to avoid precipitating opioid withdrawal)

16. Refusal to discontinue all alcohol (to reduce the risk of respiratory depression)

17. Hepatic impairment (AST/ALT > 1.5 times upper normal)

18. Estimated Glomerular Filtration Rate (GFR) < 20 ml/min

19. Inability/refusal to identify a person as an emergency contact

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• venlafaxine
slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.
• buprenorphine
randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd
• placebo
patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.

Locations

Country	Name	City	State
Canada	Centre for Addiction and Mental Health	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Centre for Addiction and Mental Health	Reckitt Benckiser LLC

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Montgomery-Asberg Depression Rating Scale	MADRS at baseline will establish study eligibility and will assess treatment-sensitive change in MDD.	32 weeks
Secondary	Suicidal Ideation Scale ( SIS)	Assess suicidal ideation and previous suicide attempts	32 weeks
Secondary	Brief Symptom Inventory for Anxiety		32 weeks
Secondary	Numeric Scale of Pain ( NRS-P)		16 weeks
Secondary	Frequency, Intensity, and Burden of Side Effects Rating (FIBSER)	Assess overall burden or degree of interference in day-to-day activities and function due to the side effects attributable specifically to the antidepressant (in this case, buprenorphine) treatment	16 weeks
Secondary	Antidepressant Side Effect Checklist (ASEC)	Assessment of side- effects	16 weeks